Schering-Plough
Article Abstract:
Schering-Plough produces Claritin which is selling well as a treatment for hay fever which does not cause drowsiness. The product accounts for some 33% of the company's earnings which is causing concern among some investors. The US authorities have approved another hay fever treatment from Hoechst and this has led to a drop in Schering-Plough's share price. Schering's Intron treatment for cancer is performing well. The company's earnings per share for 1996 are forecast at $3.28 by Goldman Sachs.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Merger signals upturn in fortunes
Article Abstract:
CeNeS Pharmaceuticals was previously known as Core, and the company has merged with CeNeS, which is providing the new management. The new company has Daniel Roach as its chief executive, and Alan Goodman as chairman. Moraxen, the company's cancer pain treatment, has performed well in trials. The company also aims to acquire products and businesses with revenue streams, so a number of deals are likely over a two-year period, and the stocks could perform well as a long-term investment.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Astra
Article Abstract:
Astra faces problems arising from a strong Swedish krona, and also faces legal action over sexual harassment claims in the US. The company also plans a New York Stock Exchange listing in May 1996. The company has seen strong sales in the US, and Pulmicort, its anti-asthma preparation, has performed well in the UK and Germany, but Japanese sales have not performed so well. Losec accounts for 45% of turnover, but is still seeing good growth.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Accountants find the going tough. Accountants hunt for new business. Much ventured, capital gained
- Abstracts: Defence bids in suspense. BAe/Marconi merger pushes Euro defence onto the runway
- Abstracts: Swiss banks: merger talks in Zurich. Bank bids resurface. Agricole to buy Indosuez
- Abstracts: Tangible, but transitional. A need for uniformity
- Abstracts: Ricardo: engine of growth. Quadrant: fight for survival